Published by Josh White on 23rd November 2021
(Sharecast News) - Life sciences company 4basebio announced a joint development agreement between its wholly owned-subsidiary 4basebio Discovery and Leucid Bio on Tuesday, which it said was pioneering "next-generation" chimeric antigen receptor T-cell (CAR-T) therapies for hard-to-treat cancers.